NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Super important point.

For an APPROVED drug, companies can work with the insurance companies to get coverage for off-label coverage based solely on real world data, which is not clinical trial data, but things like hospital records and economic data as well. The company does potentially have and likely will continue to develop data for such patients. Real World Data is not a clinical trial.

Murcidencel's non-toxic profile, its truly autologous (therefore personalized) immunotherapy nature, and therefore its systemic efficacy, make it a perfect Off-label choice for oncologist for treatment across cancers and stages of cancers.

For insurance coverage, I would assume welcoming and acceptance given how much money it will save them in the life of treating a cancer patient. DCVax's remarkable quality of life stories from patients means that by default there is not the ongoing issues and costs of recurrence and treating of toxic secondary illnesses, and the resulting hospital visits from those things, if treated with other more toxic drugs. This preventative perspective with regards to Murcidencel's non-toxic profile and the just amazing long tail survivor results should be an easy decision for insurance coverage IMO.